Introduction
============

Nutrition support is very important in all age groups, especially in children and the elderly ([@r1], [@r2]). Nutritional B12 deficiency is rare in children with nonspecific symptoms, including failure to thrive, vomiting, anorexia and neurological changes with or without hematologic disturbances. Symptoms cover a broad spectrum, including weakness, tiredness, lightheadedness, rapid heartbeat and breathing, pale skin, soreness, easy bruising and bleeding, sore tongue, gastric upset, weight loss, diarrhea or constipation, lack of motivation and energy, muscle weakness and tingling in the extremities. Other neurological findings include altered sensation, paresthesia in the extremities, gait ataxia, poor vision, dizziness, loss of taste or smell, urinary or fecal incontinence, loss of cutaneous sensation, impaired sense of vibration, proprioception, psychiatric manifestation, memory impairment, personality changes, convulsions, hypotonia, developmental delay, orthostatic hypotension, postural orthostatic tachycardia, poor activity and developmental delay. While it is common during infancy and adolescence in developing and underdeveloped countries, a high level of awareness is required in order to prevent permanent neurological damage from B12 deficiency, especially in children with mild symptoms ([@r1]). Adenosylcobalamin and methylcobalamin, two forms of vitamin B12, are co-factors in two enzymatic reactions, either or both of which may impact myelin formation. Plasma homocysteine increases in vitamin B12 deficiency ([@r3], [@r4]). An increased level of homocysteine is related to a number of neurodegenerative diseases associated with neurotoxicity and overstimulation of N-methyl-D aspartate receptors ([@r3]-[@r8]). In case of B12 deficiency, the levels of the homocysteine precursor are affected because a decreased S-adenosylmethionine:S-adenosylhomocysteine (SAM:SAH) ratio affects DNA synthesis and cell recycling, since folate cannot be recycled in the absence of cobalamin ([@r3]-[@r9]).

The objective of this study was to determine neurological presentations and characteristics of children with B12 deficiency. Since methylation reactions are very important in many parts of the nervous system, cobalamin deficiency leads to a wide range of neurological presentations.

Patients and Methods
====================

This retrospective study involved children aged 0-18 referred to the university hospital outpatient child neurology clinic in Turkey due to neurological symptoms during the 2012-2013 period. The study group consisted of 38 patients (20 male and 18 female), age range from 9 months to 17 years. Patients were classified according to their neurological signs and symptoms. Symptoms on admission are shown in [Table 1](#t1){ref-type="table"}. None of the patients had sufficient animal product foodstuffs in their diet. Diagnosis of B12 deficiency was based on serum B12 concentrations below 200 pg/mL. Data concerning sex, age and symptoms of the disease, neurological examination, laboratory investigations and magnetic resonance imaging (MRI), electroencephalography (EEG) and electromyelography (EMG) findings were collected. Laboratory investigations included vitamin B12, folic acid levels, whole blood count, hemoglobin and hematocrit, and mean corpuscular volume (MCV). Patients with neurological symptoms, serum B12 level lower than 200 pg/mL, and with normal folic acid levels were included in the study. None of the patients was on medication during the study, and none had symptoms of any parasitic or duodenal ulcer disease. Ethical approval for the study was obtained from the local ethics committee.

###### Clinical, radiological and neurophysiological features of patients with vitamin B12 deficiency

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient\   Sex   Age at presentation (years)   Neurological symptoms                                                   Hb (mg/dL)   Vitamin B12 level (pg/mL)   Cranial MRI findings   Additional test
  no.                                                                                                                                                                                    
  ---------- ----- ----------------------------- ----------------------------------------------------------------------- ------------ --------------------------- ---------------------- ----------------------------------------------------------
  1          M     12                            Syncope                                                                 13.1         159                         N                      Interictal EEG: N

  2          M     10                            Syncope                                                                 13.9         168                         N                      Interictal EEG: N

  3          F     11                            Syncope                                                                 13.9         137                         N                      Interictal EEG: N

  4          F     13                            Syncope                                                                 12.4         130                         N                      Interictal EEG: N

  5          F     17                            Syncope                                                                 9.8          154                         N                      Interictal EEG: N

  6          F     12                            Syncope                                                                 12.8         126                         N                      Interictal EEG: N

  7          M     14                            Dizziness                                                               15.3         144                         N                      

  8          F     14                            Dizziness                                                               12.1         125                         N                      

  9          F     15                            Dizziness                                                               14.3         109                         N                      

  10         M     7                             Dizziness                                                               12.2         147                         N                      

  11         M     24 months                     Hypotonia, unable to walk                                               11.0         143                         N                      

  12         M     10 months                     Hypotonia, unable to sit without support                                11.5         40                          N                      

  13         M     9 months                      Hypotonia, unable to sit without support                                11.1         172                         N                      

  14         M     10 months                     Hypotonia, unable to sit without support                                11.1         160                         N                      

  15         M     20 months                     Hypotonia, unable to walk                                               11.3         136                         NA                     

  16         M     22 months                     Hypotonia, unable to walk                                               12.5         188                         N                      

  17         F     22 months                     Hypotonia, unable to walk                                               11.5         132                         N                      

  18         F     11 months                     Hypotonia, unable to sit without support                                11.0         154                         NA                     

  19         M     24 months                     Hypotonia, unable to walk                                               12.0         135                         N                      

  20         M     5                             Gait ataxia                                                             12.5         157                         N                      

  21         M     5                             Gait ataxia                                                             11.2         196                         NA                     

  22         M     12                            Convulsion/focal                                                        12.9         120                         N                      Interictal EEG: N

  23         F     3                             Convulsion/generalized                                                  11.0         143                         NA                     Interictal EEG: N

  24         F     10 months                     Convulsion (infantile spasm)                                            13.3         136                         N                      EEG: hypsarrhymia

  25         M     6                             Convulsion/focal                                                        12.2         167                         N                      Interictal EEG: N

  26         M     15                            Tremor                                                                  15.5         135                         N                      

  27         M     16                            Tingling sensation, paresthesia (in distal part of upper extremities)   14.9         104                         NA                     EMG: bilateral sensorial neuropathy in upper extremities

  28         F     17                            Tingling sensation, paresthesia in upper distal extremities             12.3         114                         NA                     EMG: N

  29         M     8                             Tingling sensation, paresthesia in upper distal extremities             13.6         135                         NA                     EMG: N

  30         M     5                             Vision blurring                                                         13.4         146                         N                      VEP: amplitudes lower than normal on the right side

  31         F     17                            Fatigue, difficulty in concentrating, headache                          13.6         92                          N                      

  32         M     8                             Fatigue, difficulty in concentrating, headache                          14.1         98                          N                      

  33         F     14                            Fatigue, difficulty in concentrating, headache                          10.9         161                         N                      

  34         M     17                            Fatigue, difficulty in concentrating, headache                          15.1         73                          N                      

  35         F     7                             Fatigue, difficulty in concentrating, headache                          12.4         134                         N                      

  36         F     10                            Fatigue, difficulty in concentrating, headache                          12.3         141                         N                      

  37         F     8                             Fatigue, difficulty in concentrating, headache                          12.6         144                         N                      

  38         F     12                            Fatigue, difficulty in concentrating, headache                          13.4         163                         N                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Hb = hemoglobin; M = male; F = female; EEG = electroencephalography; EMG = electromyelography; VEP = visual evoked potential; MRI = magnetic resonance imaging; NA = not available; N = normal

Treatment regimen involved B12 supplementation with bolus injection of 1000 mcg/mL B12 (in the form of cyanocobalamin) intramuscularly and repeated every week for four weeks.

Statistical analysis
--------------------

Data analysis was performed using the SPSS (Statistical Package for Social Sciences) version 20 data analysis package. One-way ANOVA was used when differences between the groups were evaluated because the variables showed normal distribution. The paired-t test was used because the variance between the two dependent variables was analyzed from normal distribution. Wilcoxon test was used because the variance between the two dependent variables was not different from normal distribution. Kruskal Wallis-H test was used to analyze the variables between the groups, which did not show normal distribution. When Kruskal Wallis-H test yielded significant differences, the groups that differed were identified with the post-hoc multiple comparison test. When one-way ANOVA yielded significant differences, Tukey HSD was used when the variances in the groups were homogeneous, while Tamhane's analysis was used when the variances were not homogeneous. The level of statistically significant difference was set at p\<0.05.

Results
=======

Patient neurological findings included syncope (n=6), dizziness (n=4), hypotonia (n=9), inability to sit or walk without support, or gait ataxia (n=2), convulsion (n=4), hand tremor (n=1), tingling sensations and paresthesia (n=3), vision blurring (n=1), fatigue and concentration difficulty (n=8). Patients were divided into four groups by combining these findings together. Group 1 consisted of patients with syncope and dizziness (n=10); group 2 of patients with hypotonia findings (n=9); group 3 of patients with tingling sensations and paresthesia, fatigue, difficulty in concentrating and headache (n=11); and group 4 of those with convulsion (n=4) or other findings (hand tremor, gait ataxia, or vision blurring) (n=4).

Demographic, clinical, laboratory and imaging data are shown in [Table 1](#t1){ref-type="table"}. Thirty-eight patients, 21 male and 17 female, met the selection criteria. The syncope and dizziness group consisted of four boys and six girls, the hypotonia findings group of seven boys and two girls, the tingling sensations and paresthesia group of four boys and seven girls, and the other findings group of six boys and two girls. The mean patient age was 8.51 years. A statistically significant difference was determined among the groups according to age. The age in the hypotonia group (group 2) was significantly lower than in the groups with syncope and dizziness (group 1), and tingling-paresthesia, fatigue, difficulty in concentrating and headache (group 3) (p\<0.05).

Patient mean serum B12 level was 137.18 mg/dL. B12 distribution according to patient groups is shown in [Table 2](#t2){ref-type="table"}. Comparison of pre- and post-treatment values within the groups revealed that in the hypotonia group, the pre-treatment blood hemoglobin level was significantly lower than the post-treatment level (p\<0.05). Pre-treatment blood hemoglobin levels and post-treatment MCV levels in the hypotonia group differed from those in other groups (p=0.02 and p=0.035, respectively).

###### Distribution of age and laboratory values according to patient groups

                                                                                        n        Mean    Median   Min    Max      SD       p
  ------------------------------------------ ------------------------------------------ -------- ------- -------- ------ -------- -------- -------
  Age (years)                                Group 1                                    10       12.5    12.5     7      17       2.8      0.001
  Group 2                                    9                                          1.41     1.67    0.75     2      0.56              
  Group 3                                    11                                         12.18    12      7        17     4.14              
  Group 4                                    8                                          6.48     5       0.83     15     4.69              
  Total                                      38                                         8.51     8       0.75     17     5.68              
  B12 levels before treatment                Group 1                                    10       139.4   140.5    109    163      17.12    0.269
  Group 2                                    9                                          140      143     40       188    41.89             
  Group 3                                    11                                         123.55   134     73       163    29.32             
  Group 4                                    8                                          150      144.5   120      196    23.42             
  Total                                      38                                         137.18   139     40       196    29.68             
  B12 levels after treatment                 Group 1                                    10       609.4   590.5    430    878      168.06   0.989
  Group 2                                    9                                          722.67   644     345      2000   509.3             
  Group 3                                    11                                         727.09   587     339      2000   452.2             
  Group 4                                    8                                          658.5    585     300      1043   279.09            
  Total                                      38                                         680.63   604     300      2000   368.11            
  Blood hemoglobin levels before treatment   Group 1                                    10       12.97   12.95    9.8    15.3     1.52     0.02
  Group 2                                    9                                          11.44    11.3    11       12.5   0.51              
  Group 3                                    11                                         13.2     13.4    10.9     15.1   1.25              
  Group 4                                    8                                          12.75    12.7    11       15.5   1.42              
  Total                                      38                                         12.63    12.45   9.8      15.5   1.38              
  Blood hemoglobin levels after treatment    Group 1                                    10       13.42   13.55    11     14.8     1.12     0.051
  Group 2                                    9                                          12.19    12.3    11       13.1   0.63              
  Group 3                                    11                                         13.12    13      11.5     15.3   1.17              
  Group 4                                    8                                          13       12.6    12.2     15.4   1.05              
  Total                                      38                                         12.95    12.75   11       15.4   1.08              
  MCV before treatment                       Group 1                                    10       80.86   81.7     70.4   88.4     5.26     0.355
  Group 2                                    9                                          79.04    79.5    71.5     91.1   5.81              
  Group 3                                    11                                         82.65    80.7    78.4     89.8   4.26              
  Group 4                                    8                                          79.41    80.4    72.4     85.4   3.99              
  Total                                      38                                         80.64    80.55   70.4     91.1   4.91              
  MCV after treatment                        Group 1                                    10       80.4    81.35    73.5   83.4     3.51     0.035
  Group 2                                    9                                          77.78    77.8    73.5     81.2   2.46              
  Group 3                                    11                                         81.71    80.9    77.8     88.5   3.22              
  Group 4                                    8                                          80.4     80.35   77.3     84.7   2.24              
  Total                                      38                                         80.16    80.7    73.5     88.5   3.19              
  Group 1                                    Blood hemoglobin levels before treatment   10       12.97   12.95    9.8    15.3     1.52     0.257
  Blood hemoglobin levels after treatment    10                                         13.42    13.55   11       14.8   1.12              
  Group 2                                    Blood hemoglobin levels before treatment   9        11.44   11.3     11     12.5     0.51     0.006
  Blood hemoglobin levels after treatment    9                                          12.19    12.3    11       13.1   0.63              
  Group 3                                    Blood hemoglobin levels before treatment   11       13.2    13.4     10.9   15.1     1.25     0.722
  Blood hemoglobin levels after treatment    11                                         13.12    13      11.5     15.3   1.17              
  Group 4                                    Blood hemoglobin levels before treatment   11       13.2    13.4     10.9   15.1     1.25     0.722
  Blood hemoglobin levels after treatment    11                                         13.12    13      11.5     15.3   1.17              
  Total                                      Blood hemoglobin levels before treatment   38       12.63   12.45    9.8    15.5     1.38     0.026
  Blood hemoglobin levels after treatment    38                                         12.95    12.75   11       15.4   1.08              

MCV = mean corpuscular volume

One patient from group 4, who presented with infantile spasm, exhibited a hypsarrhythmic pattern on EEG, while the three other patients with convulsions had normal interictal EEG. The patient with infantile spasm also exhibited elevated homocysteine level (17 µmol/L) (normal range: 5-15 µmol/L) in the urinary organic acid profile. All four group 4 patients experienced no recurrence of convulsions after vitamin supplementation. Patients with tingling sensations and paresthesia (group 3) underwent EMG. One subject exhibited sensory neuropathy on EMG, while the others had normal results. Another nine group 3 patients presented with developmental motor delay and hypotonia. Four were able to sit without support and five were able to support their weight on their feet one month after vitamin supplementation. Patients who presented with fatigue and concentration difficulty recovered, but their headache persisted. All patients with syncope underwent cardiologic consultation. Patients with dizziness were referred to an otolaryngologist. No pathology was determined on otolaryngologic examination. All patients with syncope underwent pediatric cardiologic examination. Transthoracic echocardiography findings were normal, and no pathological difference was determined in blood arterial pressure values in either standing or supine position. After B12 supplementation (in the form of cyanocobalamin), serum vitamin B12 levels normalized and all symptoms except for headache resolved within one month.

Discussion
==========

Vitamin B12 is essential for development of the central nervous system. Nutritional vitamin B12 deficiency in infancy is common in countries with low intake of animal products ([@r4], [@r6]). Early treatment prevents severe neurological manifestations. Measurement of vitamin B12 levels can assist in the diagnosis of vitamin B12 deficiency. Homocysteine and methylmalonic acid levels also are elevated in B12 deficiency. Diagnosis of vitamin B12 deficiency should not rely on an abnormal hemoglobin level, hematocrit level or MCV, especially in mild cases ([@r10]). Although clinical neurological manifestations in infants have been described very well in several case studies, the underlying pathology is not yet fully understood ([@r4]).

Neurological signs may usually be expected in infants who are exclusively breastfed and who receive inadequate amounts of vitamin B12. Hypotonia and neurodevelopmental delay are the most commonly reported signs in infants. We observed hypotonia in nine cases. Clinical improvement was observed in all patients after vitamin supplementation.

Diagnosis of vitamin B12 deficiency may not cause an abnormal blood chart, especially in mild cases ([@r10]). Anemia was not a common condition in our study. A significant increase in hemoglobin values was observed only in group 2, which consisted of infants with hypotonia ([Table 2](#t2){ref-type="table"}). Vitamin B12 deficiency may be a more important factor that particularly affects blood chart in these groups. We attributed the difference in pre-treatment hemoglobin levels and post-treatment MCV levels in the hypotonia group to the age of patients in this group, which was composed of very young individuals.

Several reports have indicated a correlation between epilepsy and vitamin B12 deficiency ([@r11]-[@r13]). Rat studies have suggested that homocysteic acid, a metabolic product of homocysteine, induces convulsions ([@r11], [@r12]). There are also reports of patients with infantile spasm being successfully treated with B12 supplementation ([@r14], [@r15]). In this study, we identified two patients with focal convulsion, i.e. one with generalized convulsion and another one with infantile spasms. The patient with infantile spasm exhibited hypsarrhythmia on EEG and was treated successfully with B12 and adrenocorticotropic hormone. All patients were subsequently seizure-free. The other patient exhibited normal interictal EEG and MRI findings. Vitamin B12 deficiency can also lead to dizziness and syncope. Vitamin B12 is important in the production of adrenaline from noradrenaline. It is an essential cofactor involved in myelin degradation and in the synthesis of catecholamines. Another proposed mechanism is that myelin synthesis is disrupted in vitamin B12 deficiency and may lead to baroreflex dysfunction, affecting the sympathetic regulation of blood vessels and autonomic nervous system ([@r16]). A cause and effect relationship has also been suggested between syncope and postural orthostatic tachycardia syndrome in B12 deficiency ([@r17]). Vision loss in vitamin B12 deficiency has been regarded as secondary to optic neuropathy ([@r18]-[@r21]). In the present study, one patient had vision abnormality and pathological visual evoked potential test results. This patient also recovered within a few weeks with B12 supplementation.

Neuropsychiatric abnormalities consist of a wide range of symptoms including chronic fatigue syndrome, mood disorders, attention deficit, mental status and cognitive changes, slow mentation, memory impairment and behavioral abnormalities ([@r22], [@r23]). Patients without macrocytic anemia but with tissue cobalamin deficiency can also develop neuropsychiatric abnormalities ([@r22]). Although only one had anemia, eight of our patients were affected neuropsychologically. The absence of quantitative analysis in terms of neuropsychological tests in patients with fatigue and attention deficit was a limitation of this study. However, the fact that the symptoms resolved in a few weeks after supplementation of vitamin B12 indicates a cause-effect relationship between B12 deficiency and the symptoms in question. Patients who presented with fatigue and concentration difficulty recovered, but their headache persisted. We conclude that headache was not related to vitamin B12 deficiency because the patients did not have anemia. Additionally, polyneuropathy is a common neurological finding in patients with vitamin B12 deficiency. Polyneuropathy due to cobalamin deficiency is often axonal. Neurophysiological and pathological findings indicate axonal degeneration, whether or not accompanied by demyelination. In this study, three patients were admitted with tingling sensations and paresthesia in distal upper extremities. The pathogenic mechanism of neuropathy in cobalamin deficiency has been attributed to myelin damage involving astrocytes and microglia.

Although we made every effort to establish a large cohort with a wide variety of symptoms of vitamin B12 deficiency, this study still had a number of limitations, as follows: we were unable to screen for homocysteine and methylmalonic acid levels supporting B12 deficiency. Only the patient with infantile spasm underwent urinary and plasma amino and organic acid tests in order to exclude a diagnosis of metabolic disease; and patient symptoms and signs could not be evaluated with neuropsychological investigation.

In conclusion, vitamin B12 deficiency should be considered in patients with congenital hypotonia, syncope, gait ataxia, convulsions, vision loss or vision blurring, neuropathy, dizziness or tremor, even in the absence of anemia. Since nervous system symptoms can precede anemia by months, patients with neurological symptoms should be carefully evaluated in terms of vitamin B12 deficiency with or without associated anemia. Since immediate and accurate treatment prevents progression of the disease, a cautious and aware approach is essential. We believe that this study indicates the importance of screening for vitamin B12 in patients from low-income and populous communities and with the symptoms described.
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